DNTH Dianthus Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DNTH matters now
Dianthus Therapeutics, Inc. (DNTH) is a US stock in Healthcare. The latest InvestLog snapshot shows $97.60 with -2.43% on the session and $4.07B in market capitalization; recent performance reads 1-month -3.71% and YTD +100.17%.
The latest financial table shown here is Q1 2026, with revenue of $463.0K, net income of $-40.8M, and EPS of $-0.85. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.
The latest indexable market news headline is "Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $120.00; recent insider activity includes Veness Adam M filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.30
P/S
2577.81
EV/EBITDA
-259.40
DCF Value
$-1.95
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.3%
Operating Margin
-14318.0%
Net Margin
-847.5%
ROE
-1.8%
ROA
-0.9%
ROIC
-15.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $463.0K | $-40.8M | $-0.85 |
| Q4 2025 | $284.0K | $97.9M | $2.59 |
| FY 2025 | $2.0M | $-162.3M | $-4.20 |
| Q3 2025 | $396.0K | $-36.8M | $-0.97 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$115.00
Target (Median)
$120.00
Target Range
$55.00 - $145.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.07
Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was established in 2015 and operates from its headquarters in New York, New York.